Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

• Status: Completed
• Trial end date: 2003-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function

• Phase: Phase 3

Details

• Lead Sponsor: AstraZeneca
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• Male or female aged 18 or above

• Congestive Heart Failure with symptoms for more than 4 weeks before starting study

• Provision of informed consent

Exclusion Criteria:

• Current low blood pressure with symptoms

• Liver disease considered significant by the study doctor

• Pregnant or lactating females